About 50 million people suffer from chronic pain, while an additional 25 million suffer from acute pain, which translates to roughly $100 billion spent on treatment regimens per year.
Insight Diagnostics embraces its role with pride as a member of a team dedicated to eliminating or at least pacifying such complex ailments.
However, the majority of drugs for pain management which are available on the market have limitations and potential for both abuse and misuse.
This is why proper identification of patients is one of the concerns at Insight Diagnostics, especially if patients have aberrant drug-related issues.
The pain management plan may also include personal and family medical histories, screening surveys and treatment agreements with patients to better determine the approach to improving their health and well-being.
As opposed to drawing blood specimen, which usually requires a patient’s consent, the collection of a urine specimen is needle-free and easy.
Drugs and drug metabolites that are found in urine are typically in a stable condition, meaning that there is a high chance of distinguishing them. Urine specimens usually contain detectable levels of drug use at a high concentration and over an extended period of time.
Drugs of abuse in urine (DAU) testing often have a three-day window of opportunity to accurately detect drug abuse. However, for drugs which dissolve in lipids, fats, or oils, evidence can remain in urine for a longer period. Psychoactive drugs can last up to 21 days, while traces of cannabinoids remain in urine for up to 60 days.
Although urine testing is the most common drug testing method, it’s not foolproof. That’s why we suggest specimen validity testing. By measuring pH, creatinine and specific gravity and testing for adulterants and may be added to the urine; we can ensure the integrity of the test. Insight Diagnostics is one of the few laboratories to offer oxidant identification for some of the most common oxidizing adulterants.